NCT02804711View on ClinicalTrials.gov

A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

July 31, 2017

Study Completion Date

September 30, 2017

Conditions
Staphylococcus Aureus Infection
Interventions
BIOLOGICAL

Low dosage of Staphylococcus aureus vaccine (15µg/0.6ml)

BIOLOGICAL

Middle dosage of Staphylococcus aureus vaccine (30µg/0.6ml)

BIOLOGICAL

High dosage of Staphylococcus aureus vaccine (60µg/0.6ml)

BIOLOGICAL

Placebo

Trial Locations (1)

210009

Xiaokui Hu, Taishing

Sponsors
All Listed Sponsors
collaborator

Chengdu Olymvax Biopharmaceuticals Inc.

INDUSTRY

collaborator

Third Military Medical University

OTHER

lead

Jiangsu Province Centers for Disease Control and Prevention

NETWORK

NCT02804711 - A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults | Biotech Hunter | Biotech Hunter